FindTrial
Sign In

The effects of vaginal estrogen therapy, moisturizers, and lubricants on the number of lactobacilli in postmenopausal vaginal atrophy

The effects of vaginal estrogen therapy, moisturizers, and lubricants on the number of lactobacilli in postmenopausal vaginal atrophy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20160426005
Enrollment
Unknown
Registered
2016-04-26
Start date
2016-05-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal atrophy vaginal atrophy postmenopause vaginal estrogen therapy vaginal moisturizer vaginal lubricant

Interventions

vagianl estrogen therapy is contain conjugated estrogen CSD in a nonliquefying base. Using 1 gram of cream everyday for 2 weeks then 0.5gram of cream twice a week.,vaginal moisturizer is a non&#45
hormonal vaginal treatment. Polycarbophil&#45
based vaginal gel that binds to vaginal epithelial cells and maintains hydraion. Using one applicators three times a week.,Vaginal lubricant is a water&#45
based non&#45
hormonal vaginal treatment. Using 1 finger&#45
based of gel during sexual intercourse to relieve dyspareunia and vaginal dryness.
Active Comparator Drug,Active Comparator Device,Active Comparator Device
vaginal estrogen therapy,vaginal moisturizer,vaginal lubricant

Sponsors

Ratchadaphiseksomphot Endowment fund
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: -Naturally postmenopausal women aged 45-70 years old (using WHO criteria for retrospective amenorrhea for 12 months after final menstruation with no obvious pathological cause of amenorrhea) -At least one clinical symptom of vaginal atrophy, with moderate to severe intensity -Vaginal pH > 5

Exclusion criteria

Exclusion criteria: -Menopause from other causes (POI, hysterectomy, oophorectomy, chemotherapy, radiation) -History of vaginal or cervical procedures within the previous 3 months (LEEP, conization, cryotherapy) -Recurrent or recent vaginal inflammation or related infection within the previous 3 months -History of hormone replacement therapy, use of vaginal lubricants or local estrogen therapy within the previous 3 months -Abnormal vaginal bleeding within the previous 3 months

Design outcomes

Primary

MeasureTime frame
The number of lactobacilli first visit and 8 weeks after treatment gram stain technique and 1000x microscopic—

Secondary

MeasureTime frame
vaginal pH first visit and 8 weeks after treatment pH indicator strips,the most bothersome symptom first visit and 8 weeks after treatment the most bothersome symptom score,Species of lactobacilli 8 weeks after treatment Anaerobe Culture,Vaginal maturation index first visit and 8 weeks after treatment H&E stain and count the vaginal cells—

Countries

Thaland

Contacts

Public ContactPunkavee Tuntiviriyapun

Unaffiliated

pun_tunz@hotmail.com081-343-4243

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026